恶性肿瘤患者化疗前后淋巴细胞亚群及β_2-m的测定及临床意义

Clinical Significance of Changes of T Lymphocytes Subsets Distribution Type and Serum β_2-m Levels After Chemotherapy in Patients with Malignant Tumors

目的:探讨恶性肿瘤患者化疗前后淋巴细胞亚群及β2-m的变化及临床意义。方法:60例恶性肿瘤患者采用流式细胞术检测淋巴细胞亚群,化学免疫发光技术检测β2-m。结果:恶性肿瘤患者CD8+细胞及β2-m高于正常,而CD4+细胞及CD4+/CD8+比值显著低于正常水平(P<0.05);化疗后完全缓解组以上四项趋于正常(P>0.05);而未缓解组与完全缓解组及正常对照组相比有明显差异(P<0.05)。结论:恶性肿瘤患者均有免疫功能异常,治疗有效后免疫功能恢复正常。

Objective To study the T lymphocyte subsets and serum 132 - m level changes in patients with malignant tumors after chemotherapy and the implied clinical significance. Methods The T lymphocyte subsets were examined with flowcytometry and serum β2 - m levels were measured with CLIA in 60 patients with various kinds of malignancies both before and after 4 cycles of chemotherapy as well as in 30 controls. Results Before chemotherapy, the CD8 percentage and β2 - m level in the patients were significantly higher than those in controls （ P 〈 0.05 ）. On the contrary, the CD4 percentage and CD4/CD8 ratio in the patients were significantly lower than those in controls （P 〈 0.05 ）. After chemothorapy, the value in the patients with satisfactory remission （n = 18 ） were not much different from those in controls, while values in the remaining 42 patients were still significantly different from those in controls （P 〈0. 05 ）. The difference between the values in the two groups of patients was also significant （ P 〈 0.05 ）. Conclusion Patients with malignant tumors suffered from immunofunction damage. After effective treatment, this impairment might be corrected.